News
-
According to Beckley Psytech, the company has initiated a Phase 2a study of its BPL-003 intranasal dry powder 5-MeO-DMT for the treatment of moderate-to-severe treatment-resistant depression. Beckley Psytech recently reported results from a Phase 1… Read more . . .
-
Aerami Therapeutics has announced that its current Chief Operating Officer Lisa Yañez will succeed Steve Thornton as CEO, effective January 1, 2023. Thornton will continue as a member of the Board of Directors. Prior to… Read more . . .
-
Israel-based SpliSense said that it has initiated a Phase 1/2 trial of its SPL84 inhaled anti sense oligonucleotide for the treatment of cystic fibrosis associated with the 3849+10 kb C-to-T mutation. SPL84 has been granted… Read more . . .
-
Vistagen, which is developing two pherine-based nasal sprays licensed from Pherin Pharmaceuticals (PH10 and PH94B), announced that it has reached an agreement to acquire Pherin and its entire pipeline. According to Vistagen, the deal includes… Read more . . .
-
Verona Pharma announced that the Phase 3 ENHANCE-1 trial of nebulized ensifentrine for the treatment of COPD met its primary endpoint, demonstrating an average change from baseline in FEV1 AUC, 0-12 hours post dose, of… Read more . . .
-
Florida-based CDMO Formulated Solutions announced that it has acquired a 455,000 sq ft production facility in Cleveland, TN, USA that includes two buildings fitted with pharmaceutical production and packaging lines for a variety of dose forms… Read more . . .
-
Posted on OINDPnews on December 19, 2022 Job Information:An employment opportunity is available for a Postdoctoral Associate in the laboratory of Dr. Heidi Mansour at the Center of Translational Science (https://cts.fiu.edu/people/mansour-heidi/) located in the beautiful… Read more . . .
-
Inhaled nitric oxide (iNO) delivery device developer Third Pole Therapeutics announced that it has received a $32 million equity investment “from a large medical device innovator.” In February 2022, the company announced the closing of… Read more . . .
-
According to Virpax Pharmaceuticals, the FDA has provided guidance in response to the company’s pre-Investigational New Drug NobrXiol (VRP324) CBD nasal powder, which Virpax is developing for the for the treatment of epilepsy. In September 2021,… Read more . . .
-
According to Aridis Pharmaceuticals, the Cystic Fibrosis Foundation has made a $4.85 million investment in Aridis common stock to support continued development of AR-501 nebulized gallium citrate for the treatment of chronic lung infections in CF… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.